New eczema cream tested in teens – early results expected
NCT ID NCT07329101
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a cream called VC005 in 11 adolescents aged 12 to 18 with mild to moderate eczema. The main goal was to check safety and how the body processes the drug. Researchers measured drug levels in the blood and looked for side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- VC005 cream
- What this could lead to
- If it works, this could point toward a new topical treatment for eczema in teens.
- What could go wrong
- This is a very early Phase 1 trial with only 11 participants, so it is too small to prove effectiveness. The main goal is safety, not symptom relief.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
11 people
The number who actually took part.
- Started
-
Nov 2025
- Finished
-
Feb 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * When giving informed consent, the age range is 12-18 years old (including 12 years old), with no gender restrictions; * The subjects and their guardians voluntarily sign an informed consent form (dated), indicating that the subjects have been informed of all relevant parts of the study; * All women and all men with the potential to conceive must be willing to use at least one highly effective method of contraception from the time of signing the informed consent form until 3 months after the last administration of the investigational drug Exclusion Criteria: * Subjects suspected to be allergic to VC005 gel or to excipients in VC005 gel, or with ≥ 2 kinds of drug allergy history in the past; * The researchers believe that there may be skin injuries or abnormalities in the subjects that could affect the evaluation of the administration site of the investigational drug； * The researchers believe that the subjects have clinically relevant skin diseases that are contraindicated in the study or affect the evaluation of the administration site, including but not limited to psoriasis, acne, dysplastic nevi, and skin cancer;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.